Every emerging biopharmaceutical company has an interesting story that describes how they overcame major startup challenges, including study design, funding, and drug targeting strategies. eXIthera is developing a small molecule, EP-7041, to control the blood-clotting pathway and enable healthy blood flow without the concerns of adverse clotting or major bleeding via selective inhibition of Factor […]

Every emerging biopharmaceutical company has an interesting story that describes how they overcame major startup challenges, including study design, funding, and drug targeting strategies. eXIthera is developing a small molecule, EP-7041, to control the blood-clotting pathway and enable healthy blood flow without the concerns of adverse clotting or major bleeding via selective inhibition of Factor […]

After holding a ringside seat watching the growing team at BlueRock build up an advanced preclinical set of regenerative stem cell projects in the pipeline, Bayer wants to own it all. Bayer execs struck a deal to buy out the 60% of the shares it didn’t already own, paying $240 million in cash and setting […]